What results can you expect from the Wegovy injection?

What did the clinical trials actually find?

The headline figure (roughly 15% average weight loss over 68 weeks) is meaningful, but the detail behind it matters. STEP 1 randomised 1,961 adults with a BMI of 30 or above (or 27-plus with at least one weight-related condition) and no type 2 diabetes. Participants using semaglutide 2.4 mg lost an average of around 14.9% of body weight; the placebo group lost about 2.4%. About one third of semaglutide participants lost 20% or more.

Results did not arrive overnight. The titration schedule means most people spend the first four to five months moving up through 0.25 mg, 0.5 mg, 1.0 mg and 1.7 mg before reaching 2.4 mg, the dose at which the trial evidence was measured. If the first few weeks feel slow, that reflects the design, not a failure. The NHS semaglutide medicines page has a plain-English summary of how the medicine works and what to expect at each stage.

The MHRA approved a 7.2 mg single-dose pen in April 2026. Trials at this higher dose reported around 20.7% average weight loss over 72 weeks. That narrows the gap with tirzepatide at its highest dose, which is worth knowing if you are comparing the two options. Specific dose availability is confirmed at consultation, our prescribers discuss this as part of the clinical review.

How long does it take to see results with the Wegovy injection?

This is the question our prescribers hear most often, and the honest answer is: it depends on where you are in the titration schedule. Most people notice reduced appetite within the first week or two. Meaningful weight loss on the scale, however, tends to build through months two to six, accelerating once the maintenance dose is established.

If you are curious about injection technique and whether it affects how the medicine is absorbed, where you inject Wegovy can make a practical difference to comfort and consistency. Rotating between the abdomen, thigh and upper arm is recommended in the product information.

Plateau periods are common and do not mean the medicine has stopped working. Weight loss often stalls while the body adjusts, then resumes. A prescriber can help you interpret what is happening, which is one reason clinical oversight throughout treatment matters, not just at the start. For a broader look at how the medicine is used week to week, our guide to the Wegovy injection covers the practical side in more detail.

Stopping treatment typically leads to some weight regain over time; this is a pharmacological reality, not a personal failing. The STEP 1 follow-up data showed most participants regained the majority of lost weight within a year of stopping. Treatment decisions about duration should be discussed with your prescriber.

Who tends to see the strongest results from Wegovy?

Across the STEP trial programme, people with higher starting BMIs, those who made consistent dietary changes alongside treatment, and those who reached and stayed on the maintenance dose for the full trial period tended to see greater absolute weight loss. That pattern is consistent with how appetite-based medicines work: semaglutide reduces hunger, but the choices made while hunger is lower still shape outcome.

The licensed indication for Wegovy is adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, NICE's appraisal of semaglutide (TA875) sets out the clinical criteria used in NHS settings, which gives useful context even for people accessing treatment privately.

Results are also influenced by how comfortable someone is with the injection itself. If self-injecting feels daunting, understanding the best place to inject Wegovy for the most consistent results can reduce the anxiety that sometimes leads people to skip doses.

For context on how Wegovy injection results compare with other weight-loss medicines available in the UK, the weight-loss treatment overview sets out the options clearly, and the cost context for private treatment is covered on the Wegovy where to buy page if that is useful.

What affects results in practice, and what the trials cannot tell you?

Trial data captures averages under controlled conditions. Real-world results vary because real life is messier: missed doses, illness, periods of high stress, changes in activity and dietary habits all shift the outcome. The trial participants had regular contact with clinical teams; that wraparound support is part of why results were strong.

Side effects can also shape the picture. Gastrointestinal effects (nausea, loose stools, indigestion, reduced appetite to the point of eating too little) are common early in treatment and after each dose increase. They typically settle within a week or two, but during that window some people eat less than they intended, which can affect energy levels and nutritional balance. Staying hydrated and maintaining adequate protein intake matters.

If side effects are affecting your experience or you have questions about your progress, aftercare support exists for exactly this reason. At nume, a prescriber reviews every repeat order before it is approved, not as a formality, but to catch issues like the ones above early. You can also reach the clinical team through the contact page seven days a week.

If you are wondering whether Wegovy is the right option for your situation, checking eligibility takes a few minutes and costs nothing. Check your eligibility with our prescribers and get a same-day clinical review if you are suitable.